Market Overview:
The global H3N2 infection treatment market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The market growth is attributed to the increasing incidence of H3N2 infections, rising demand for better and advanced therapeutics, and growing awareness about the benefits of early diagnosis and treatment. Based on type, the global H3N2 infection treatment market is segmented into APP-309, Aspidasept, C-05, CR-8020, and others. The APP-309 segment accounted for the largest share of the global market in 2017 owing to its high efficacy in treating various types of viral infections. Based on application, the global H3N2 infection treatment market is segmented into clinic settings, hospital settings,, and other settings such as long term care facilities or homecare settings.
Product Definition:
H3N2 is a virus that causes severe respiratory illness in people. It is important to receive treatment for H3N2 infection as soon as possible to help prevent serious health complications. Treatment options include antiviral medications and antibiotics, depending on the underlying cause of the infection.
APP-309:
App- 309 is a new influenza virus with high pathogenicity and transmissibility. It was first detected in poultry in China in April 2019. Since then, it has been identified across the globe including Europe, North America, Asia Pacific and Australia. The emergence of this novel flu virus is a global concern that requires an urgent response from the healthcare industry to combat against this emerging threat of pandemic level infectious disease spread.
The major difference between seasonal flu.
Aspidasept:
Aspidasept is an enzyme that digest the viral particles in the host cell. It is found in plants, bacteria and fungi. Aspidasept treatment for H3N2 infection works by breaking down the protective coating of viruses which are then absorbed by white blood cells and liver cells. The breakdown products of as pidasept are then used by various organs to produce proteins, fats & other chemicals essential for their functioning.
Application Insights:
Based on the application, the global market is segmented into an outpatient clinic, hospital and others. The out-patient clinic held the largest share of over 60% in 2017 owing to its low cost and easy accessibility for patients. It also has a lower barrier to entry as compared with other types of facilities such as hospital or clinics that offer in-house H3N2 treatment.
The hospital segment is expected to witness lucrative growth during forecast years due to rising incidences of severe infections caused by this virus across hospitals globally coupled with increasing investments by governments in building modern healthcare infrastructure at a domestic level. In addition, growing awareness about these types of facilities among people living within proximity to an affected area will further boost product demand during this period.
The others category includes commercial centers, private practices.
Regional Analysis:
North America dominated the global market in terms of revenue share in 2017. The region is expected to maintain its dominance over the forecast period as well owing to factors such as favorable government initiatives, high healthcare expenditure and availability of advanced treatment options. Asia Pacific is anticipated to witness lucrative growth during the forecast period due to increasing awareness about novel treatment methods and rising incidence of seasonal flu infections. Moreover, growing medical tourism industry will also boost demand for h3n2 infection treatment products in this region.
The European market was valued at USD X million in 2017 and is expected to grow at a significant rate over the forecast period owing to an increase in research funding for new drug development along with approval and launch of novel H1N1 vaccines globally including Europe (Shingrix) along with other vaccines against future pandemics (FluGen). In addition, CROs are providing services across major European countries offering flexible dates & times for treatments which further increases patient access thus driving regional growth.
Growth Factors:
- Increasing incidence of H3N2 infection
- Rising demand for better treatment options for H3N2 infection
- Growing awareness about the benefits of early diagnosis and treatment of H3N2 infection
- Technological advancements in the field of H3N2 Infection Treatment 5. increasing funding for research and development in the field of H3N2 Infection Treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
H3N2 Infection Treatment Market Research Report
By Type
APP-309, Aspidasept, C-05, CR-8020, Others
By Application
Clinic, Hospital, Others
By Companies
AIMM Therapeutics B.V., Aphios Corporation, Crucell N.V., CSL Limited, Glide Pharmaceutical Technologies Limited, ILiAD Biotechnologies, LLC, Inovio Pharmaceuticals, Inc., Johnson & Johnson, Medicago Inc., MedImmune, LLC, Mucosis B.V., NanoViricides, Inc., Novavax, Inc., OPKO Health, Inc., Sarepta Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Visterra, Inc., Zydus Cadila Healthcare Limited
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
173
Number of Tables & Figures
122
Customization Available
Yes, the report can be customized as per your need.
Global H3N2 Infection Treatment Market Report Segments:
The global H3N2 Infection Treatment market is segmented on the basis of:
Types
APP-309, Aspidasept, C-05, CR-8020, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AIMM Therapeutics B.V.
- Aphios Corporation
- Crucell N.V.
- CSL Limited
- Glide Pharmaceutical Technologies Limited
- ILiAD Biotechnologies, LLC
- Inovio Pharmaceuticals, Inc.
- Johnson & Johnson
- Medicago Inc.
- MedImmune, LLC
- Mucosis B.V.
- NanoViricides, Inc.
- Novavax, Inc.
- OPKO Health, Inc.
- Sarepta Therapeutics, Inc.
- Takeda Pharmaceutical Company Limited
- Visterra, Inc.
- Zydus Cadila Healthcare Limited
Highlights of The H3N2 Infection Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- APP-309
- Aspidasept
- C-05
- CR-8020
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the H3N2 Infection Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no specific treatment for H3N2 infection, but general measures to reduce the risk of getting sick include staying healthy and avoiding close contact with people who are sick. If you do get sick with H3N2, your doctor will likely prescribe antibiotics to help treat the infection.
Some of the major players in the h3n2 infection treatment market are AIMM Therapeutics B.V., Aphios Corporation, Crucell N.V., CSL Limited, Glide Pharmaceutical Technologies Limited, ILiAD Biotechnologies, LLC, Inovio Pharmaceuticals, Inc., Johnson & Johnson, Medicago Inc., MedImmune, LLC, Mucosis B.V., NanoViricides, Inc., Novavax, Inc., OPKO Health, Inc., Sarepta Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Visterra, Inc., Zydus Cadila Healthcare Limited.
The h3n2 infection treatment market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 H3N2 Infection Treatment Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 H3N2 Infection Treatment Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 H3N2 Infection Treatment Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the H3N2 Infection Treatment Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global H3N2 Infection Treatment Market Size & Forecast, 2020-2028 4.5.1 H3N2 Infection Treatment Market Size and Y-o-Y Growth 4.5.2 H3N2 Infection Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 APP-309
5.2.2 Aspidasept
5.2.3 C-05
5.2.4 CR-8020
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global H3N2 Infection Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 H3N2 Infection Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 APP-309
9.6.2 Aspidasept
9.6.3 C-05
9.6.4 CR-8020
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 APP-309
10.6.2 Aspidasept
10.6.3 C-05
10.6.4 CR-8020
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 APP-309
11.6.2 Aspidasept
11.6.3 C-05
11.6.4 CR-8020
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 APP-309
12.6.2 Aspidasept
12.6.3 C-05
12.6.4 CR-8020
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 APP-309
13.6.2 Aspidasept
13.6.3 C-05
13.6.4 CR-8020
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 H3N2 Infection Treatment Market: Competitive Dashboard
14.2 Global H3N2 Infection Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AIMM Therapeutics B.V.
14.3.2 Aphios Corporation
14.3.3 Crucell N.V.
14.3.4 CSL Limited
14.3.5 Glide Pharmaceutical Technologies Limited
14.3.6 ILiAD Biotechnologies, LLC
14.3.7 Inovio Pharmaceuticals, Inc.
14.3.8 Johnson & Johnson
14.3.9 Medicago Inc.
14.3.10 MedImmune, LLC
14.3.11 Mucosis B.V.
14.3.12 NanoViricides, Inc.
14.3.13 Novavax, Inc.
14.3.14 OPKO Health, Inc.
14.3.15 Sarepta Therapeutics, Inc.
14.3.16 Takeda Pharmaceutical Company Limited
14.3.17 Visterra, Inc.
14.3.18 Zydus Cadila Healthcare Limited